Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Money33. I think UYG is a good to have morenext week.
I'm holding FAS over the weekend. I just feel this will move further with the Stimulus Package and all the other Financial stuff going on in the next week or two.
GTCB: I sold my last 1K and bought it back again at .75. I'm fickle. Here is the reason: the news of using animal as a host for a treatment is very big for the Pharma R&D. More will follow. I would think they have patents on the technologies which would mean loyalties. Being the first to get FDA approval is big. Who knows what opportunities are open for them.
LGND-Nice play Sheff
I'm totally out. Sold the first half a couple of days ago with your post at .91 and sold half a little bit ago at .71. I was in a .60. Made a little profit. I held on the the 2nd half because I could not believe this did not go to at least $1.
Agree. I guess some boards just have too much time on their hands and are very very bored.
It's more huge than the money itself. Technologically and scientifically it's very very huge.
GTCB Seems like the shook some out and it's moving very nicely now.
It came over Fidelity.
Moved back up a little. I sold most of mine at .91 from my entry of .60. Just have 1K and still at a profit. I'm going to hold a little longer.
I would feel better if the price did not drop.
Sheff- GTCB received FDA approval.
For anyone in GTCB. They just received FDA approval for Atryn.
Thought so. Weeeeee. This is one I am playing in my smaller Etrade account. I have 400 shares averaged in at 4.49 and up $533.00. A good example making bank with less.
Chart- do we have a exit strategy or are you thinking we hold over the weekend.
Sounds like the farm areas which are very beautiful in the summer. I live right off Highway 295 which is very convenient to and literally across the street from Moorestown which was voted by Forbes as the most desirable city to live in a couple of years ago.
Jake. I live in Mount Laurel, Southern NJ. Where did you move to?
ABK is moving up nicely.
Stimulus package to get voted on tonight between 5-7:00.
Good Morning. Looks like we are going to have a Weeeeeeee Day.
Sheff, I hope you a speedy recovery.
Good Morning Everyone. CTIC New:
Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
01:30 a.m. 02/05/2009 Provided by
SEATTLE, Feb. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTIC) (CTI) announced today that it has issued 6,634 shares of Series F Preferred Stock in exchange for 6,634 shares of CTI's Series A, B and C Convertible Preferred Stock. The exchange constitutes 83% in interest of all series of CTI's Convertible Preferred Stock. Each share of the new Preferred Stock will become convertible into 7,143 shares of CTI's common stock, at a conversion price of $0.14 per common share representing a significant premium to the current market price.
The Series F Preferred Stock cannot become convertible into common stock sooner than April 1, 2009. Additionally, the Company has the ability to redeem all, but not less than all, of the outstanding Series F Preferred Stock for cash when the Volume-Weighted Average Price (VWAP) has exceeded $0.28 for ten previous trading days. The Series F Preferred Stock does not provide a redemption right for the holders as did the Series A, B and C Convertible Preferred Stock, thereby eliminating the possibility that the Company could be required to make involuntary cash redemption payments of approximately $6.6 million on the preferred stock that was exchanged. The Series F Preferred Stock does not bear a fixed dividend rate.
"We are pleased that almost all of the remaining preferred shareholders were willing to trade in their securities and enable CTI to avoid their redemption rights and dividend payments, saving the company approximately $6.6 million over the next 6 months, for a meaningful equity position in the Company upon their conversion into common stock," noted James A. Bianco, M.D., CEO of CTI. "With the prospects for three drug approvals in 2009, we believe they chose to participate based on the price appreciation potential of CTI should we be successful with the approvals this year."
About Cell Therapeutics, Inc. (CTIC)
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.
This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
CTIC News:
Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
01:30 a.m. 02/05/2009 Provided by
SEATTLE, Feb. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTIC) (CTI) announced today that it has issued 6,634 shares of Series F Preferred Stock in exchange for 6,634 shares of CTI's Series A, B and C Convertible Preferred Stock. The exchange constitutes 83% in interest of all series of CTI's Convertible Preferred Stock. Each share of the new Preferred Stock will become convertible into 7,143 shares of CTI's common stock, at a conversion price of $0.14 per common share representing a significant premium to the current market price.
The Series F Preferred Stock cannot become convertible into common stock sooner than April 1, 2009. Additionally, the Company has the ability to redeem all, but not less than all, of the outstanding Series F Preferred Stock for cash when the Volume-Weighted Average Price (VWAP) has exceeded $0.28 for ten previous trading days. The Series F Preferred Stock does not provide a redemption right for the holders as did the Series A, B and C Convertible Preferred Stock, thereby eliminating the possibility that the Company could be required to make involuntary cash redemption payments of approximately $6.6 million on the preferred stock that was exchanged. The Series F Preferred Stock does not bear a fixed dividend rate.
"We are pleased that almost all of the remaining preferred shareholders were willing to trade in their securities and enable CTI to avoid their redemption rights and dividend payments, saving the company approximately $6.6 million over the next 6 months, for a meaningful equity position in the Company upon their conversion into common stock," noted James A. Bianco, M.D., CEO of CTI. "With the prospects for three drug approvals in 2009, we believe they chose to participate based on the price appreciation potential of CTI should we be successful with the approvals this year."
About Cell Therapeutics, Inc. (CTIC)
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.
This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
You know someone just mentioned RFMD. I think it was Jake.
I joined you with adding 5K at .3594. Needed to do a little cost averaging.
Mine is in my IRA also. I'm just placed an order for 5K to average down at .14. Let's see if I get it.
Anybody still in NRGN? Looks like it may finally be starting to move up.
Coach: Your not kidding. I'm in that one at .44. Ouch.
I sold half mine also at .36 on your que. I still have 2.5K.
CYTR: What price are we looking for here?
Silver: I hope so. I'm in that one at 4.00.
I am averaged down to .075. The bid moved up. Is this a good sign that they are getting ready to move it? I don't usually play pennies.
Thanks!
I think we will see this in the teens again soon.
I have FAS and will hold.
If the Stimilus Bill is signed as promised by Presidents Day, the financials should do okay. So will the market as a whole. JMHO
I just joined you in BAC at 5.15 for a little.
I'm in with 1K CENX in my IRA. I think I will be buying more today if it dips this morning in my Brokerage account.
Chart. I am in the same situation as your brother-in-law. I am very interested in what you play in his account. I just got margin on the account so I can trade without waiting 3 days. I am thinking about buying CENX on any dip this morning. Do you think it's still a good time to get in?
It's a very tough job market out there. I have been looking for a new job since September. Recruiters are having a hard time getting the opportunities and once the do, it's not odd for the positions to fizzle out. Just wanted to share that with you so you understand what he will be going through. I don't have children at home so my pressure is different.
Good Morning Everyone.